Ponatinib for Squamous Cell Lung and Head and Neck Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01761747
Recruitment Status : Terminated (FDA hold and toxicity associated with study drug)
First Posted : January 7, 2013
Results First Posted : December 23, 2014
Last Update Posted : December 23, 2014
Information provided by (Responsible Party):
Peter S. Hammerman, Dana-Farber Cancer Institute

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Non-Small Cell Lung Cancer, Head and Neck Cancer
Intervention: Drug: ponatinib

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Ponatinib Treatment Arm

Ponatinib taken by mouth daily


Participant Flow:   Overall Study
    Ponatinib Treatment Arm

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Ponatinib Treatment Arm

Ponatinib taken by mouth daily


Baseline Measures
   Ponatinib Treatment Arm 
Overall Participants Analyzed 
[Units: Participants]
[Units: Years]
Mean (Full Range)
 (37 to 74) 
[Units: Participants]
Female   0 
Male   3 
Race/Ethnicity, Customized 
[Units: Participants]
Caucasian   3 
Region of Enrollment 
[Units: Participants]
United States   3 
Disease [1] 
[Units: Participants]
[1] Non-small cell lung cancer

  Outcome Measures

1.  Primary:   Response Rate of Patients With Lung or Head and Neck SCC Treated With Ponatinib   [ Time Frame: 2 years ]

2.  Secondary:   Prevalence of Specific FGFR Amplifications/Mutations in the Study Population   [ Time Frame: 2 years ]

3.  Secondary:   Progression-free Survival   [ Time Frame: 2 years ]

4.  Secondary:   Define Toxicities of Ponatinib   [ Time Frame: 2 years ]

5.  Secondary:   Overall Survival   [ Time Frame: 2 years ]

6.  Secondary:   Disease Control   [ Time Frame: 2 years ]

7.  Secondary:   Determine the Correlation FGFR Amplifications/Mutations With Patient Age, Sex, Disease Stage, Prior Response to Treatment and Smoking History   [ Time Frame: 2 years ]

8.  Secondary:   Define the Response Rate to Ponatinib is Patients With FGFR Amplifications Versus Mutations   [ Time Frame: 2 years ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Dr. Peter Hammerman
Organization: Dana-Farber Cancer Institute
phone: 617-632-6335

Responsible Party: Peter S. Hammerman, Dana-Farber Cancer Institute Identifier: NCT01761747     History of Changes
Other Study ID Numbers: 12-327
First Submitted: September 26, 2012
First Posted: January 7, 2013
Results First Submitted: November 15, 2014
Results First Posted: December 23, 2014
Last Update Posted: December 23, 2014